secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-056669
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q1 net loss widens to $19.8M; positive Phase 1a data for ATI-052
------------------------------------------------------------------------

- Net loss $19.8M vs $15.1M YoY; revenue $2.0M (+33%) on higher Lilly/Sun Pharma royalties.
- Cash & equivalents $190.8M (up from $151.4M); raised $59.8M via 18.4M share ATM offering in March.
- ATI-052 Phase 1a SAD/MAD showed half-life ~45 days, sustained target engagement up to 20 wks; supports Q3-month dosing.
- Phase 1b POC trials in asthma and atopic dermatitis ongoing; top line results expected H2 2026.
- Completed enrollment in bosakitug Phase 2 AD trial; results expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/0001104659-26-056669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/acrs-20260507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-056669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer